Adlai Nortye Ltd. American Depositary Shares (ANL)vsModerna Inc (MRNA)
ANL
Adlai Nortye Ltd. American Depositary Shares
$15.21
+0.80%
HEALTHCARE · Cap: $979.49M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 12239% more annual revenue ($2.23B vs $18.06M). ANL leads profitability with a -124.8% profit margin vs -141.4%. ANL earns a higher WallStSmart Score of 28/100 (F).
ANL
Avoid28
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ANL.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 178.1% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -12.9% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ANL
The strongest argument for ANL centers on Revenue Growth, Debt/Equity. Revenue growth of 178.1% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ANL
The primary concerns for ANL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ANL profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
ANL is growing revenue faster at 178.1% — sustainability is the question.
ANL generates stronger free cash flow (-8M), providing more financial flexibility.
Bottom Line
ANL scores higher overall (28/100 vs 21/100) and 178.1% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adlai Nortye Ltd. American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?